RT @IHSMarkit: "If you want to take care of shareholders, you better take care of your people, and you better take care of your planet, and…
Assessing market access risk: Understanding pricing, cost, and market trends webinar
In July, IHS launched its pharmaceutical Market Access Risk Scores (MARS), which are designed to quantify the relative risks of global pharmaceutical markets, both for launching new medicines and maintaining the life cycle of already-launched products, in one comparative framework. Built up on 42 qualitative and quantitative metrics, the new service feature immediately garnered significant attention as the first pharma-specific risk rating system of its kind, with significant discussion over our findings.
Risk ratings in action
In our initial country sample, Venezuela was found to be the riskiest market with an overall risk score of 4.21 (or "Very High"). Perhaps unsurprisingly, the United States was seen as the least risky market - but it was only by a marginal score, and it was still found to be a market with a significant "Moderate" risks (at 2.28), reflecting the complexity and growing burdens of operating in the world's largest pharma market. In between the two, there were several countries with perhaps unexpected scores, reflecting the fact that occasionally market perception is not the same as market reality. In addition to this, there were many interesting and complex findings among the subratings, including how various markets rated in qualitative areas such as intellectual property, international reference pricing, reimbursement mechanisms and generic substitution.
These ratings can play an important role in mapping the global market opportunities for pharmaceutical companies, providing significant comparative insight both into where to make investments for a company's expanding global infrastructure, as well as understand where the relative risks lie for global launch sequencing and life cycle management strategies. This is particularly critical as companies seek to understand the dynamic between developed and emerging markets whilst weighing their portfolio and pipeline opportunities against their risks.
Join us for our webinar on Wednesday 25 September at 15:00 London time (10 am New York time), where we will be discussing the assessment of market access risk, and delve into some of our findings - using both our MARS framework as well as our international pharmaceutical pricing data (POLI) and global analytical expertise. register here
- The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September
- Is the US ready to start relaxing COVID-19 lockdowns?
- COVID-19 could cause delays for price framework agreements in parts of Europe
- US scrambles for resources in COVID-19 response
- COVID-19: Risk of severe complications among the United States health workforce
- COVID-19 pandemic: Health system surge capacity
- UK bans parallel export of two COVID-19 treatment candidates to protect national supply
- China’s young biosimilars sector
The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September https://t.co/9fX4R1K8rC